Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms

Neuropsychiatric symptoms (NPSs) are hallmarks of Alzheimer's disease (AD), causing substantial distress for both people with dementia and their caregivers, and contributing to early institutionalization. They are among the earliest signs and symptoms of neurocognitive disorders and incipient c...

Full description

Saved in:
Bibliographic Details
Published inAlzheimer's & dementia : translational research & clinical interventions Vol. 3; no. 3; pp. 440 - 449
Main Authors Lanctôt, Krista L., Amatniek, Joan, Ancoli-Israel, Sonia, Arnold, Steven E., Ballard, Clive, Cohen-Mansfield, Jiska, Ismail, Zahinoor, Lyketsos, Constantine, Miller, David S., Musiek, Erik, Osorio, Ricardo S., Rosenberg, Paul B., Satlin, Andrew, Steffens, David, Tariot, Pierre, Bain, Lisa J., Carrillo, Maria C., Hendrix, James A., Jurgens, Heidi, Boot, Brendon
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.09.2017
John Wiley & Sons, Inc
Elsevier
Subjects
Agitation
Alzheimer's disease
Anxiety
Apathy
Brain research
Caregivers
Clinical trials
Delusions
Dementia
Depression
Hallucinations
Hypothalamus
Institutionalization
Mental depression
Mortality
Neurobiology
Neuropsychiatric symptoms
Neurosciences
Older people
Psychosis
Psychotropic drugs
Review
Sleep
Sleep disturbance
Trial design
Apathy
Sleep disturbance
Agitation
Neuropsychiatric symptoms
Delusions
Trial design
Hallucinations
Depression
Alzheimer's disease
Online AccessGet full text

Cover

More Information
Summary:Neuropsychiatric symptoms (NPSs) are hallmarks of Alzheimer's disease (AD), causing substantial distress for both people with dementia and their caregivers, and contributing to early institutionalization. They are among the earliest signs and symptoms of neurocognitive disorders and incipient cognitive decline, yet are under-recognized and often challenging to treat. With this in mind, the Alzheimer's Association convened a Research Roundtable in May 2016, bringing together experts from academia, industry, and regulatory agencies to discuss the latest understanding of NPSs and review the development of therapeutics and biomarkers of NPSs in AD. This review will explore the neurobiology of NPSs in AD and specific symptoms common in AD such as psychosis, agitation, apathy, depression, and sleep disturbances. In addition, clinical trial designs for NPSs in AD and regulatory considerations will be discussed.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2352-8737
2352-8737
DOI:10.1016/j.trci.2017.07.001